Estrella Immunopharma近日宣布，已正式激活俄勒冈健康与科学大学（OHSU）作为其Starlight-1 I/II期临床试验的第三家临床中心。该试验聚焦于治疗B细胞非霍奇金淋巴瘤，旨在评估新型疗法的安全性与有效性。这一里程碑标志着公司扩展临床网络、加速试验进程的最新举措。
Estrella Immunopharma近日宣布，已正式激活俄勒冈健康与科学大学（OHSU）作为其Starlight-1 I/II期临床试验的第三家临床中心。该试验聚焦于治疗B细胞非霍奇金淋巴瘤，旨在评估新型疗法的安全性与有效性。这一里程碑标志着公司扩展临床网络、加速试验进程的最新举措。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.